Holen Sie sich die Stockscreener-App
0.6508
4.23%
0.0264
Vorhandelsmarkt:
.66
0.0092
+1.41%
Schlusskurs vom Vortag:
$0.6244
Offen:
$0.62
24-Stunden-Volumen:
1.66M
Relative Volume:
1.18
Marktkapitalisierung:
$65.58M
Einnahmen:
$147.75M
Nettoeinkommen (Verlust:
$-284.23M
KGV:
-0.2221
EPS:
-2.93
Netto-Cashflow:
$-317.54M
1W Leistung:
+22.95%
1M Leistung:
+79.28%
6M Leistung:
-22.44%
1J Leistung:
-27.83%
1-Tages-Spanne:
$0.5721
$0.6993
1-Wochen-Bereich:
$0.4934
$0.755
52-Wochen-Spanne:
$0.18
$2.93
Fibrogen Inc Stock (FGEN) Company Profile
Firmenname
Fibrogen Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO, CA
Vergleichen Sie FGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.6508 | 65.58M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2020-05-01 | Eingeleitet | Cowen | Market Perform |
| 2020-04-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-05-29 | Fortgesetzt | Goldman | Neutral |
| 2019-05-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-02-11 | Fortgesetzt | Stifel | Buy |
| 2018-12-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-08-08 | Bestätigt | Leerink Partners | Outperform |
| 2017-08-08 | Bestätigt | Stifel | Buy |
| 2017-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2016-02-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
| 2015-12-04 | Eingeleitet | Citigroup | Buy |
| 2015-09-23 | Eingeleitet | Lake Street | Hold |
| 2015-07-29 | Eingeleitet | Citigroup | Buy |
| 2015-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2014-12-09 | Eingeleitet | Stifel | Buy |
Alle ansehen
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan
State Street Corp Lowers Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
FibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.com - MarketBeat
Court of Chancery Applies Well-Settled Principles To Dismiss Malone/Caremark ‘Hybrid’ Claims - Skadden, Arps, Slate, Meagher & Flom LLP
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
Recent Investment Analysts’ Ratings Updates for FibroGen (FGEN) - Defense World
Fmr LLC Boosts Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
HC Wainwright Comments on FibroGen FY2024 Earnings - Defense World
HC Wainwright Upgrades FibroGen (NASDAQ:FGEN) to Strong-Buy - Defense World
HC Wainwright Estimates FibroGen FY2026 Earnings - Defense World
FibroGen started at buy by H.C. Wainwright (FGEN:NASDAQ) - Seeking Alpha
FibroGen shares rating initiated with Buy on product potential By Investing.com - Investing.com Canada
FibroGen shares rating initiated with Buy on product potential - Investing.com
FibroGen appoints David DeLucia CFO - MSN
FibroGen names David DeLucia as new CFO By Investing.com - Investing.com Canada
FibroGen Appoints David DeLucia as CFO - TipRanks
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - Marketscreener.com
FibroGen names David DeLucia as new CFO - Investing.com
FibroGen Appoints David DeLucia as Chief Financial Officer - GlobeNewswire
FibroGen Names David DeLucia as New CFO to Lead Financial Strategy and Drug Development Push - StockTitan
FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com - Defense World
Analyzing Unicycive Therapeutics (NASDAQ:UNCY) and FibroGen (NASDAQ:FGEN) - Defense World
FibroGen Inc earnings beat by $0.14, revenue topped estimates - Investing.com Nigeria
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN) - Defense World
ARMISTICE CAPITAL, LLC Reduces Stake in FibroGen Inc - GuruFocus.com
FibroGen Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com India
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: FibroGen reports strong Q3 sales, advances in oncology pipeline - Investing.com UK
FibroGen: Q3 Earnings Snapshot - mySA
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - MSN
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions - Yahoo Finance
FibroGen Reports Strong Q3 Growth and Future Plans - TipRanks
FibroGen Inc (FGEN) Q3 2024 Earnings: Revenue Surges to $46.3M, EPS at $(0.17), Exceeding Estimates - GuruFocus.com
FibroGen Reports Third Quarter 2024 Financial Results - GlobeNewswire
FibroGen Q3 Revenue Surges 15% as China Sales Soar; Narrows Net Loss by 73% | FGEN Stock News - StockTitan
FibroGen Inc (FGEN) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Finanzdaten der Fibrogen Inc-Aktie (FGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrogen Inc-Aktie (FGEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 07 '24 |
Buy |
1.91 |
50,000 |
95,470 |
470,178 |
0.08%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):